Copper prices rose to around $6.44 due to tight supply in China, where warehouse stocks hit their lowest since January 2024. Local smelter maintenance limited refined copper availability, pushing buyers to imports despite record-high premiums. The US dollar's recent strength pressured copper prices, but a slight easing supported a rebound. The market now focuses on upcoming US inflation data, which could influence the US dollar and copper prices; hot inflation may strengthen the dollar and weigh on copper, while soft readings could boost copper by weakening the dollar. Technical analysis shows copper must break above $6.64 to continue rising, with strong support near $6. A drop below $6 could lead to further declines toward $5.20, but the long-term trend remains bullish due to demand from sectors like AI construction.
Copper price developments provide context for readers, with Pluang market data showing 107 of 150 US stocks rose while 39 fell as of Nov 09, 2026 14:11 WIB. Devon Energy Corp (DVN) traded at USD 42.67, down 3.29% in one day. IQIYI Inc (IQ) and Coinbase Global (COIN) also declined by 3.11% and 3.10%, respectively, with typical hold times on Pluang of 57 and 80 days.
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to redistribute excess cash to shareholders and reduce share capital. As of early November 2026, the company has repurchased approximately 7.69 million shares ...
AL Sydbank A/S executed transactions to buy back 30,000 shares during week 45 as part of its ongoing share buyback program announced in February 2026, which totals DKK 1.1 billion. The program started in March 2026 and will conclude by January 2027, ...
AL Sydbank A/S continued its share buyback program in week 45, purchasing 30,000 shares at an average price of around 725 DKK, totaling approximately 21.76 million DKK. The buyback program, announced in February 2026 and running until January 2027, a...
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
